BIOGEN INC 5.2 percent 15Sep2045 is a Senior Unsecured Note issued by the corporate entity on the 10th of September 2015. BIOGEN is trading at 95.30 as of the 3rd of December 2024, a 0.49% up since the beginning of the trading day. The bond's open price was 94.84. BIOGEN has about a 40 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Ratings for BIOGEN INC 52 are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of December 2022 and ending today, the 3rd of December 2024. Click here to learn more.
Biogen Inc. is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Companys products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. More on BIOGEN INC 52
Our tools can tell you how much better you can do entering a position in BIOGEN without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio File Import Now
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
BIOGEN financial ratios help investors to determine whether BIOGEN Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIOGEN with respect to the benefits of owning BIOGEN security.